A rational approach to the management of recurrent or persistent ovarian carcinoma

• Published in: Clinical obstetrics and gynecology Vol. 55; no. 1; p. 114
• Main Author: Thigpen, Tate
• Format: Journal Article
• Language: English
• Published: United States 01.03.2012
• Subjects: Antibodies, Monoclonal, Humanized - therapeutic use; Antineoplastic Agents - therapeutic use; Antineoplastic Combined Chemotherapy Protocols - therapeutic use; Bevacizumab; Carboplatin - therapeutic use; Chemotherapy, Cancer, Regional Perfusion; Decision Making; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Disease Progression; Doxorubicin - analogs & derivatives; Doxorubicin - therapeutic use; Drug Resistance, Neoplasm; Female; Humans; Neoplasm Recurrence, Local - pathology; Neoplasm Recurrence, Local - therapy; Neoplasm Staging; Ovarian Neoplasms - pathology; Ovarian Neoplasms - therapy; Ovary - surgery; Paclitaxel - therapeutic use; Polyethylene Glycols - therapeutic use; Quality of Life; Randomized Controlled Trials as Topic
• ISSN: 1532-5520
• DOI: 10.1097/grf.0b013e31824b9bc5

Evidence supports the current paradigm for the management of patients with recurrent or persistent ovarian carcinoma. The paradigm requires that patients be classified as platinum-sensitive or platinum-resistant. Patients who achieve a complete response with platinum-based therapy and experience at least 6 months free from recurrence should be categorized as having chemosensitive disease and should be retreated with carboplatin-based doublets. Patients who progress while receiving treatment, whose best response is stable disease, or who experience a complete response of <6 months duration should be categorized as having chemoresistant disease and should be treated with a nonplatinum single agent.